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Various laboratory studies have indicated that haematological
malignancies may be amenable to immune targeting. In B-
lymphoma (Kwak et al, 1992; Wen and Lim, 1997) and multiple
myeloma (Wen et al, 1998a, 1998b; Lim and Bailey-Wood, 1999),
efforts have been concentrated primarily on the targeting of the
idiotypic proteins or peptides. In leukaemias, various fusion genes
arising due to specific chromosomal translocation have been the
targets (Pawelec et al, 1996). Whole cell immunization strategies
(Choudhury et al, 1997; Coleman et al, 1997; Lim et al, 1998)
further supported the presence of immunogenic peptides, which
could be recognized by host T-cells. A recent study (Sahin et al,
1995) suggested that tumour cells often elicit multiple specific
immune responses in the autologous host. Whilst some tumour
antigens associated with haematological malignancies are well
known, others remain to be determined.
A new class of tumour antigens, known as CT (cancer/testis)
antigens, has recently been described (Old and Chen, 1998). They
include members of the MAGE family, BAGE and GAGE. They
are normal testicular antigens expressed aberrantly in tumour cells.
The restricted normal expression of these antigens makes them
ideal molecules for immune targeting. Most of these antigens have
been isolated through serological screening of expression recom-
binant libraries constructed from tumour RNA. Whilst the expres-
sion of these antigens in normal tissues and in solid tumour cells
are established (Chen et al, 1997), evidence relating to the pattern
of expression in haematological malignancies is scarce.
Expression of MAGE-1, MAGE-3, BAGE and GAGE-1,2 have
been investigated in leukaemias (reviewed by van den Eynde and
van der Bruggen, 1997) but their expression was not demonstrated
except in T-cell leukaemias related to HTLV-1 infection. In this
study, we have examined the expression of a panel of three known
CT antigens, SSX2, NY-ESO-1 and SCP1, in tumour cells derived
from a cohort of patients with haematological malignancies and
leukaemia cell lines, CEM, HL60 and Molt 4.
MATERIALS AND METHODS
A total of three leukaemia cell lines (CEM, HL60 and Molt 4), six
normal bone marrow and 107 tumour specimens (30 chronic
myeloid leukaemia (CML), 52 acute myeloid leukaemia (AML), 20
multiple myeloma (MM) and five acute lymphoblastic leukaemia
(ALL) were analysed. All samples were collected at disease presen-
tation without any prior therapy. All 30 CML were in chronic phase
of the disease. The French–American–British (FAB) subtypes of the
52 AML were: ten M1, 26 M2, four M3, nine M4 and three M5.
Total RNA was isolated from tumour cells using standard
RNAzol method. The mRNA expression of these CT antigens was
evaluated using reverse transcription (RT) and polymerase chain
reaction (PCR). RT was carried out in each sample using random
hexamer primers on 1 mg of total RNA. The PCR primers for each
of the CT antigen are: NY-ESO-1: ESO-1A, 5¢-CAC ACA GGA
TCC ATG GAT GCT GCA GAT GCG G-3¢ and ESO-1B, 5¢-CAC
ACA AAG CTT GGC TTA GCG CCT CTG CCC TG-3¢ (Chen et
al, 1997); SSX2: SSX2A, 5¢-GTG CTC AAA TAC CAG AGA
AGA TC-3¢ and SSX2B, 5¢-TTT TGG GTC CAG ATC TCT CGT
G-3¢ (Gure et al, 1997); SCP1: SCP1A, 5¢-CTA CTG TCT GCA
GCT TGG-3¢ and SCP1B, 5¢-CTC GTT TCG AGC TCA GTT-3¢.
These primer pairs amplify cDNA segments of 300–400 bp in
lengths. PCR was performed using 35 amplification cycles in a
thermal cycler at annealing temperature of 60°C for NY-ESO-1,
65°C for SSX2 and 55°C for SCP1. Each set of PCR reactions
contained a positive control of cDNA derived from normal testis
and a negative control of all the PCR reaction mixture except for
cDNA which was substituted with water. The integrity of RNA
was checked in each PCR reaction by multiplex amplification for
the c-abl gene segment. All positive amplifications, as visualized
on ethidium bromide agarose gels, were confirmed by two inde-
pendent RT-PCR and the specificity of the PCR products by
Southern blot analysis using the respective probes derived from
the PCR amplification products of testicular cDNA.
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RESULTS
Table 1 shows the mRNA expression of these CT antigens in
tumour cells derived from haematological malignancies. All three
antigens were not detected in normal bone marrow. SCP1 mRNA
was detected in 2/20 (10%) myeloma, 3/52 (5.7%) AML and 7/30
(23%) CML samples. Of the three AML giving a PCR product,
SCP1 was detected in two M2 and one M4. It was, however, not
detected in all three leukaemia cell lines. In all cases, amplification
of  c-abl was successful. Although the PCR was not designed
primarily to give accurate mRNA quantitation, the reproducibly
much less intense radiography signals obtained from Southern blot
analysis when compared to those obtained with normal testicular
PCR products would suggest low levels of SCP1 expression in
tumour cells derived from haematological malignancies (Figure
1). In contrast to SCP1, SSX2 and NY-ESO-1 were not detected in
any of the 107 tumour specimens and three leukaemia cell lines
evaluated.
DISCUSSION
Recent advances in tumour immunology and immunotherapy have
been in part due to the successful identification of tumour anti-
gens. In this study, we set out to determine the gene expression of
three known CT antigens in haematological malignancies because
information relating to these antigens had been derived primarily
from solid tumours. Detection of these antigens in haematological
malignancies may permit their use for immune targeting in these
malignancies.
Using the techniques of RT-PCR followed by Southern blot
analysis, we did not detect any transcripts for NY-ESO-1 and SSX-
2 in any of the tumour samples. Taken together with a previous
study showing the lack of expression of NY-ESO-1 in ten
lymphoma samples (Chen et al, 1997) and SSX2 in 14
leukaemia/lymphoma (Tureci et al, 1998a), it is likely that these
transcripts are rarely expressed in haematological malignancies. In
contrast to NY-ESO-1 and SSX-2 and a previous study including
14 leukaemia/lymphoma in which the SCP1 transcript could not
be detected (Tureci et al, 1998b), we have found that the expres-
sion of SCP1 in the tumour cells from some haematological malig-
nancies. SCP1 is involved in the pairing of chromosomes during
meiosis. It is at present the only CT antigen with a known function.
It has been identified as a member of the CT antigen following
serological screening of a recombinant cDNA library derived from
tumour cells, indicating its ability to elicit immune responses in
the cancer host. Its expression in haematological malignancies has
never been previously reported. Although its mRNA expression is
probably much lower than that in normal testis, its prevalence,
especially amongst patients with CML may suggest a potential
role for its use for immune targeting of the leukaemia. This obvi-
ously would require the appropriate processing and presentation of
the peptide in association with the host MHC molecules. Its low
level of expression may not be a problem if primary immune
responses could first be triggered with synthetic peptides since
target recognition by T-cells requires only very low copy number
of peptides on the cell surface. Further work is ongoing to deter-
mine the in vivo immunogenicity of the SCP1 antigens in patients
with tumour cells expressing the SCP1 mRNA.
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